Crinetics Pharmaceuticals Profit Margin

The latest profit margin for CRNX is -1257.79% as of June 2026. That compares with -26568.53% in the prior-year period — up 95.3% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Crinetics Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, CRNX's profit margin moved from -26568.53% to -1257.79% — a 95.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Crinetics Pharmaceuticals's valuation or profitability profile.

Against Healthcare companies, CRNX currently prints -1257.79% for profit margin, while the sector average sits near 14.34%. That is roughly 8868.3% below the sector mean. Large gaps often invite a closer look at Crinetics Pharmaceuticals's growth, margins, and balance sheet.

Profit Margin shows how effectively Crinetics Pharmaceuticals converts resources into returns. At -1257.79%, CRNX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -26568.53% in the prior-year period — up 95.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CRNX's profit margin (-1257.79%), review year-over-year change from -26568.53%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.